anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Pelvic exenteration provides significant survival benefits for selected patients diagnosed with locally advanced rectal cancer. However, in-hospital postoperative morbidity such as abdominal abscess, sepsis, and anastomotic leak remain highly prevalent, which can have short/long-term impacts on patient quality of life (QoL). The aim of this study was to determine the influence of postoperative morbidity on QoL outcomes in patients following pelvic exenteration.
METHODS: This prospective cohort study included patients who underwent pelvic exenteration at a tertiary teaching hospital in Sydney, between 2008 and 2023. QoL measures were collected at baseline, 6, 12, 18, 24, 36, 48, and 60 months using the short-form 36 (SF-36v2) survey. The predictors included variables relating to postoperative morbidity, including hospital and ICU length of stay (LOS), post-discharge mortality and the number of postoperative complications. Mixed-effects analyses were used to determine the influence of these postoperative outcomes on physical and mental QoL trajectories.
RESULTS: This study included 674 patients, with a median age of 61 years. Shorter hospital and ICU LOS, and fewer or no postoperative complications were associated with higher physical QoL scores across all time points. Conversely, postoperative morbidity did not exhibit a significant impact on mental QoL scores. Furthermore, there was a longitudinal improvement in mental QoL outcomes compared to baseline, independent of postoperative morbidity.
CONCLUSION: Postoperative morbidity significantly impacted physical QoL outcomes after pelvic exenteration, whereas mental QoL outcomes were not influenced. Interventions aimed at mitigating postoperative morbidity may hold the potential to enhance long-term QoL outcomes following pelvic exenteration.
How ancestry-associated genetic variance affects disparities in the risk of polygenic diseases and influences the identification of disease-associated genes warrants a deeper understanding. We hypothesized that the discovery of genes associated with polygenic diseases may be limited by the overreliance on single-nucleotide polymorphism (SNP)-based genomic investigation, as most significant variants identified in genome-wide SNP association studies map to introns and intergenic regions of the genome. To overcome such potential limitations, we developed a gene-constrained, function-based analytical method centered on high-risk variants (hrV) that encode frameshifts, stopgains or splice site disruption. We analyzed the total number of hrV per gene in populations of different ancestry, representing a total of 185 934 subjects. Using this analysis, we developed a quantitative index of hrV (hrVI) across 20 428 genes within each population. We then applied hrVI analysis to the discovery of genes associated with type 2 diabetes mellitus (T2DM), a polygenic disease with ancestry-related disparity. HrVI profiling and gene-to-gene comparisons of ancestry-specific hrV between the case (20 781 subjects) and control (24 440 subjects) populations in the T2DM national repository identified 57 genes associated with T2DM, 40 of which were discoverable only by ancestry-specific analysis. These results illustrate how a function-based, ancestry-specific analysis of genetic variations can accelerate the identification of genes associated with polygenic diseases. Besides T2DM, such analysis may facilitate our understanding of the genetic basis for other polygenic diseases that are also greatly influenced by environmental and behavioral factors, such as obesity, hypertension and Alzheimer's disease.
The invention is in the field of health promoting or health restoring capabilities of insect fat. The invention relates to an insect composition for use as a medicament, and for use in a method for the prophylaxis or treatment of (intestinal) inflammation in a subject. The composition comprises lauric acid. Furthermore, the invention relates to a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition. The invention also relates to the use of the insect fat composition in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. In addition, the invention relates to animal feed supplement, ingredient or product or use of the insect fat composition in the preparation of an animal feed supplement, ingredient or product. Finally, the invention relates to a (non-)therapeutic method of prophylaxis, maintaining or treatment of (intestinal) inflammation in a subject. Preferably, the insect is larvae of black soldier fly (BSF).
PURPOSE: The current quasi-experimental study aimed to develop and evaluate a virtual staff training on age-related hearing loss at a care organization for older adults.
METHOD: Training included the use of affordable headset amplifiers and a hands-on activity in which hearing loss was simulated. Staff were encouraged to offer amplifiers to assist in communication given the high prevalence of untreated hearing loss among older adults and the increased communication difficulty that results from mask-wearing.
RESULTS: Quantitative results (N = 51) from the pre/post questionnaire suggest that staff members gained knowledge about hearing loss and communication through the training session. Qualitative data over the 6-month post training suggest that some older adults had not only improved speech understanding but also improved quality of interactions with staff. The main reasons for not using the amplifiers were that staff would forget they had access to the amplifiers or the older adult would refuse to use the device.
CONCLUSION: This article highlights successes of the training as well as ideas for future trainings suggested by staff members. A key finding was the need to identify a core group of staff members who would be charged with facilitating use of personal amplification for older adults in the organization. In addition, providing multiple brief trainings over time was suggested to improve adoption of good communication practices among staff. [Journal of Gerontological Nursing, 50(4), 48-56.].
Ovarian cancer is the leading cause of death for patients with gynecologic malignancies. In most cases, the disease is diagnosed at an advanced stage and approximately 75% of patients will eventually experience disease recurrence. However, the overall response rates of second-line chemotherapy for recurrent ovarian cancer are only 20-27%. Therefore, it is important to seek alternative agent that can improve the outcome. Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets VEGFR,FGFR,PDGFR,and c-kit,. The preclinical studies suggest anlotinib may be effective in other cancers such as ovarian cancer. Therefore, the purpose of this study is to test the efficacy and safety of the study drug anlotinib.
Adolescent childbirth is associated with worse physical function over the long-term. Differential loss of muscle strength during pregnancy and postpartum for adolescents compared to adults may be one explanation for this, but research examining these differences is lacking. The objective of this study as to assess hand grip strength and hip adduction muscle strength in adolescents and adults during pregnancy and postpartum. A prospective cohort study was carried out with adolescent (13 to 18 years) and adult (23 to 28 years) primigravid women. Assessments were performed at three timepoints: before the 16th gestational week, during the third trimester, and between the fourth and sixth week postpartum. Hand grip strength (continuous and muscle weakness if ≤ 20.67 kgf) and hip adductor measures (continuous and muscle weakness if ≤ 13.8 kgf) were assessed using dynamometry. Generalized estimating equations modelled longitudinal relationships between muscle weakness and age group. More adolescents had hip adductor weakness than adults in the third trimester of pregnancy (62.5% vs. 31.8%, p < 0.005), which was corroborated by the longitudinal analyses. For all women, there were higher odds of hip adductor weakness in the third trimester (OR = 4.35; p< 0.001) and postpartum (OR = 9.45; p < 0.001) compared to the 16th gestational week. No significant difference in HGS was observed between age groups or across the different timepoints. The higher proportion of hip adductor weakness among adolescents may indicate a need for resistance training during and after pregnancy and physical therapy if weakness or injury is noted.
The present invention relates to a composition for delaying, preventing and treating age-related macular degeneration, wherein the composition comprises ginseng/red ginseng extracts and ginsenoside as an active ingredient. More particularly, the present invention relates to a composition for delaying, preventing and treating age-related macular degeneration, wherein the composition comprises, as an active ingredient, ginseng/red ginseng extracts and ginsenoside for normalizing the function of the Bruch's membrane of an eye. The present invention relates to a composition for preventing and treating vision deterioration, wherein the composition comprises ginseng/red ginseng extracts and ginsenoside as an active ingredient. More particularly, the present invention relates to a composition for preventing and treating vision deterioration, wherein the composition comprises, as an active ingredient, ginseng/red ginseng extracts and ginsenoside for normalizing the function of the Bruch's membrane of an eye. Degenerative changes of the transport function of the Bruch's membrane resulting from aging cause eyesight failure in aged persons, and in severe cases, such degenerative changes may ultimately cause an age-related macular degeneration which can lead to blindness. The composition of the present invention may remove substances deposited on the Bruch's membrane and improve the transport function of the Bruch's membrane so that the Bruch's membrane may be regenerated through cell reactions in retinal pigment epithelium (RPE). The treatment disclosed in the present invention may prevent and treat functional eye failure as a result of degeneration with age. The deterioration of the function of transporting vitamin A, essential metal and antioxidants which pass through the Bruch's membrane may cause eyesight failure in aged persons, and said failure can be prevented just by taking medicine comprising the composition of the present invention. The composition of the present invention may improve the transport function of the aging Bruch's membrane, and may prevent eyesight failure of the ordinary aged person and patient suffering from age-related macular degeneration. The composition of the present invention can be applied to an ordinary person to enable his/her eyesight to be kept healthy, and has the effects of delaying or treating the progress of diseases of the persons with the risk of age-related macular degeneration and patients suffering from age-related macular degeneration. The composition of the present invention removes waste matters deposited on the Bruch's membrane, separates enzymes which are necessary for the recovery of the membrane but are coupled to the membrane and thus may not be used, and improves the regenerating ability of the Bruch's membrane through an activation of RPE.
The present invention corresponds to a novel Bacillus subtilis NRRLB-50213 strain producing secondary metabolites, bioactive substances and degrading enzymes. This bacterium and/or the derivatives thereof has properties to formulate functional food with high contents of starch and/or soy flour. The bacterium also inhibits the growth of pathogen microorganisms. The functional food formulated with the NRRLB-50213 strain and the high concentrations of vegetable flour have the capability of generating a growth, weight gain and survival equal to or higher than the food containing high contents of fish flour or other animal protein. The invention also includes methods and formulas for increasing the growth, the weight gain and the survival percentage, since they improve and maximize the degradation and assimilation of the functional food based on vegetable flours and the Bacillus subtilis NRRLB-50213 strain. In addition, the functional food based on the present invention protects animals, s ince the same prevents diseases caused by pathogen microorganisms from appearing.
The present invention relates to an anti-cancer medicinal composition which belongs to the technical field of drugs. The anti-cancer medicinal composition comprises medicinal supplementary materials, tetrazine class drugs packaged in the medicinal supplementary materials, guanine, guanine derivatives or guanine analogs, wherein the guanine, the guanine derivatives or the guanine analogs can suppress the DNA repair function in cells, and can reduce the tolerance of tumor cells for the tetrazine class drugs. The medicinal supplementary materials mainly comprise high molecular biologic capacitability polymers which can be degraded and absorbed, and in the degradation and absorption processes, the anti-cancer drug can be released slowly at part of a tumor, so that the systemic toxicity reactions of human bodies are reduced obviously. Simultaneously, the anti-cancer drug can be applied to part of the tumors for keeping the effective drug concentration. The composition is put on part of the tumor, which can reduce the medicinal systemic toxicity reactions and simultaneously increase the drug concentration of part of the tumor in a selective mode. The treatment effect of non-operative treatment modes, such as chemotherapeutics, radiotherapy, etc., can be enhanced.
<P>PROBLEM TO BE SOLVED: To provide a medicine bag wearing tool capable of sufficiently demonstrating medicine effects that Chinese herbs have, easily putting a medicine bag on an abdominal part or the like using a medicine bag holding body without troublesomeness or the like, and improving a wearing feeling or the like.  <P>SOLUTION: The medicine bag wearing tool is provided with the medicine bag 20A for housing the Chinese herbs which emit medicine effective components as a gas and the medicine bag holding body 30 for holding the medicine bag 20 in the state of being applied to the abdominal part (the navel 5 and the peripheral part). The medicine bag holding body 30 is composed of a belt-like body (band) which can be wound around the abdominal part (body part). On an inner peripheral surface side near one end part of the medicine bag holding body 30, an inner pocket 40 for housing the bag in a rectangular shape for housing the medicine bag 20 filled with the Chinese herbs, which is slightly larger than the medicine bag 20A and whose upper side part is opened is provided. On the inner peripheral surface side at the other end part of the medicine bag holding body 30, a fastener 35 for length adjustment composed of a hook-and-loop fastener for tightening and fixing the medicine bag holding body 30 matched with the length of a waistline is provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The gastrointestinal tract has a role in thyroid physiology. Thyroid hormone is metabolized mainly in the liver, where it is conjugated to glucurunides and sulfates. These conjugation products are then excreted in the bile. Free hormones are released in the intestine and finally reabsorbed, completing the enterohepatic circulation of thyroid hormone. A very small portion of the daily production of thyroxin (T4) and triiodothyronine (T3), less than 10 percent, is excreted in the stool (1-3). In people with normal thyroid function, this pathway of T4 and T3 recirculation contributes so little to hormone availability that patients who have gastrointestinal disease or are receiving drugs that decrease T4 absorption do not have abnormal thyroid function (4). However, the thyrotoxic states are characterized by an increased enterohepatic circulation of thyroid hormones, as well as an increased urinary and fecal excretion of both conjugated and free T4 (5,6).

Cholestyramine, an ionic exchange resin sequesters T4 in the intestine and increases its fecal excretion. These phenomena were proven in hamsters in mid 1960s (7). Experimentally, it has been shown that 50 mg of cholestyramine can bind approximately 3000 μg of T4 (8) and therefore can enhance the clearance of thyroid hormones. Because of the increased enterohepatic circulation of thyroid hormones during hyperthyroidism, attempts have been made to sequester these hormones in the intestine using ionic exchange resins (9-13). Cholestyramine therapy has been studied in the treatment of thyrotoxicosis as an adjunctive therapy to thionamides, and has been found to decrease thyroid hormone levels rapidly. In several trials, cholestyramine in combination with methimazole (MMI) or propylthiouracil, caused a more rapid decline in thyroid hormone levels than standard therapy with thionamides alone (9-11,13). In all of these trials, cholestyramine was dosed at 4 grams orally two to four times a day.

This study was conducted to examine the efficacy of combination therapy of lower doses of cholestyramine with MMI and propranolol for treating patients with Graves' hyperthyroidism.
Patients receive olaparib PO BID on days 1-3, 8-10, 15-17, 21-23 and carboplatin IV and paclitaxel IV on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study, as clinically indicated, and optionally at the end of treatment.
BACKGROUND: In the hospital setting, frailty is a significant risk factor, but difficult to measure in clinical practice. We propose a reweighting of an existing diagnoses-based frailty score using routine data from a tertiary care teaching hospital in southern Germany.
METHODS: The dataset includes patient characteristics such as sex, age, primary and secondary diagnoses and in-hospital mortality. Based on this information, we recalculate the existing Hospital Frailty Risk Score. The cohort includes patients aged ≥ 75 and was divided into a development cohort (admission year 2011 to 2013, N = 30,525) and a validation cohort (2014, N = 11,202). A limited external validation is also conducted in a second validation cohort containing inpatient cases aged ≥ 75 in 2022 throughout Germany (N = 491,251). In the development cohort, LASSO regression analysis was used to select the most relevant variables and to generate a reweighted Frailty Score for the German setting. Discrimination is assessed using the area under the receiver operating characteristic curve (AUC). Visualization of calibration curves and decision curve analysis were carried out. Applicability of the reweighted Frailty Score in a non-elderly population was assessed using logistic regression models.
RESULTS: Reweighting of the Frailty Score included only 53 out of the 109 frailty-related diagnoses and resulted in substantially better discrimination than the initial weighting of the score (AUC = 0.89 vs. AUC = 0.80, p < 0.001 in the validation cohort). Calibration curves show a good agreement between score-based predictions and actual observed mortality. Additional external validation using inpatient cases aged ≥ 75 in 2022 throughout Germany (N = 491,251) confirms the results regarding discrimination and calibration and underlines the geographic and temporal validity of the reweighted Frailty Score. Decision curve analysis indicates that the clinical usefulness of the reweighted score as a general decision support tool is superior to the initial version of the score. Assessment of the applicability of the reweighted Frailty Score in a non-elderly population (N = 198,819) shows that discrimination is superior to the initial version of the score (AUC = 0.92 vs. AUC = 0.87, p < 0.001). In addition, we observe a fairly age-stable influence of the reweighted Frailty Score on in-hospital mortality, which does not differ substantially for women and men.
CONCLUSIONS: Our data indicate that the reweighted Frailty Score is superior to the original Frailty Score for identification of older, frail patients at risk for in-hospital mortality. Hence, we recommend using the reweighted Frailty Score in the German in-hospital setting.
In Part 1 of the study RO7248824 and \[89Zr\]-labeled RO7248824 will be administered as a single bolus IT injection following a standard IT Administration procedure. In Part 2 of the study, it is planned to test up to 3 additional IT procedures. This part is tentative with regard to its conduct and the number of procedures that may be tested.
The purpose of this three year study is to develop and then test the feasibility and acceptability of a uniquely targeted HIV risk reduction intervention for young men who have sex with men (MSM), ages 16 to 20, at risk for HIV acquisition or transmission. In year one, the preliminary components of a primary prevention intervention for young MSM aged 16-20 will result from the findings of qualitative interviews conducted among a multiethnic sample of 21 young MSM (aged 18-24) who acquired HIV through male-to-male sexual contact between ages 16-20. In year two, a preliminary primary prevention intervention curriculum will be completed and subsequently refined through community advisory board review. In year three, the feasibility and acceptability of the intervention will be tested in a two-arm randomized controlled trial in a community-based agency with excellent access to and research experience with the population. We will enroll 100 at-risk young MSM ages 16-20; two-thirds of the sample (N=66)will be randomized to the intervention condition while one-third (N=34) will be randomized to the time-matched attention control condition and receive standard health promotion information in a group-based format. Sexual risk will be assessed at baseline, 6, and 12 weeks post-intervention. The specific aims of this exploratory study are: 1) to design an HIV and substance use primary prevention program for 16-20 year-old urban, ethnically-diverse YMSM; 2) to pilot test and refine study methods; 3) to test the revised multi-ethnic intervention with 100 young YMSM and examine preliminary effects on risky sexual behavior, alcohol/drug use, and psychosocial intermediate outcomes specified by our theoretical framework in preparation for a large-scale, efficacy study. An additional exploratory aim is to describe the prevalence of HIV and STIs in the community recruited sample.
Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
A cluster randomized controlled trial design was adopted. The major subjects of SME (Sharing, Mind, Enjoyment) App Pilot Project RCT Study are 300-500 middle school students. Two schools will be recruited and randomized to each group. Schools will either be assigned to app intervention group or waitlist control group. The students in the intervention group will use the App for one month. Daily and Weekly tasks related to SME will be assigned through the App, and information related to mental health will be provided. The waitlist control group will be able to use the App after we finish all the assessments.

There will then be 4 assessments (pre-intervention, immediate post-intervention, one month and three months after) to evaluate the effects of the intervention programme. In the assessments, students will be asked to complete a questionnaire to measure the changes in SME (sharing, mind and enjoyment) related behaviors, changes of knowledge and attitude towards the anxiety disorder, changes of happiness and well-being.